Zuellig Pharma launches Lilly’s Mounjaro in Thailand

27 May 2025

Leading healthcare solutions company Zuellig Pharma has announced that Mounjaro (tirzepatide), Eli Lilly’s (NYSE: LLY) blockbuster diabetes and obesity drug, will be launched in Thailand at the end of May 2025.

Zuellig Pharma holds the marketing authorization for Mounjaro in Thailand, having been granted the distribution and promotion rights for the medicine by Eli Lilly this year.

Tirzepatide is also sold as Zepbound for the obesity indication, and generated first-quarter 2025 global sales of $2.31 billion, up 100% year-on-year, while Mounjaro sales were $3.84 billion, up 113%. The brands are the leading GLP-1 agents in this space and compete with Novo Nordisk’s semaglutide, sold as Wegovy and Ozempic.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK